New Study Evaluates the Performance of Masimo SpHb ® Noninvasive Spot-Check Hemoglobin in the Emergency Department
Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud University Medical City and Dar Al Uloom University (Riyadh, Saudi Arabia) evaluated the performance of noninvasive spot-check hemoglobin measurement with Masimo SpHb® on emergency department (ED) patients. The researchers found that SpHb provided “acceptable accuracy and excellent correlation” with their invasive laboratory measurements and offers an “easy, quick, feasible, cheap, and accurate solution for Hb measurement in the ED.”1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230108005059/en/
Masimo Rad-67® with SpHb® (Photo: Business Wire)
Noting that invasive blood hemoglobin measurement, while an important step in the management of blood loss, has drawbacks such as “consumption of valuable time, phlebotomy-induced anemia, pain, infection, and more involvement of human resources and equipment,” the authors sought to evaluate whether a noninvasive modality might offer similarly accurate results while mitigating some of these factors. To compare noninvasive and invasive measurements, they enrolled 650 patients (age > 14 years) who visited the EDs of two hospitals within King Saud University Medical City between March and May 2022 and needed complete blood count measurements. Hemoglobin was noninvasively measured (SpHb) using the Masimo Rad-67® handheld Pulse CO-Oximeter® with the DCI®-mini fingertip sensor. Simultaneously, blood samples were collected and analyzed at the time of collection (LabHb) using their automated analyzer, a UniCel DxH 800 Coulter Cellular Analysis System.
The researchers found a “highly significant correlation” between SpHb and LabHb (Pearson correlation coefficient = 0.812, p < 0.01). Bland-Altman analysis revealed low mean bias of 0.146 g/dL ± 1.39 g/dL, with moderate limits of agreement (-2.58 and 2.87 g/dL) and a margin of error (95% confidence interval) of 2.7 g/dL.
The researchers concluded that “noninvasive hemoglobin (SpHb) measurement showed acceptable accuracy and excellent correlation with LabHb and provided an easy, quick, feasible, cheap, and accurate solution for Hb measurement in the ED. Further research is required to study its effects on patient outcomes and blood transfusion and time and cost effectiveness.”
SpHb is not intended to replace laboratory blood testing. Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering, among other factors, patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples.
@Masimo | #Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.2 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,3 improve CCHD screening in newborns,4 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.5-8 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,9 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.10 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius Tº® and the Masimo W1™ watch. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.
ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
- Al Aseri ZAA, Aldawood BA, Altamimi et al. Accuracy of noninvasive hemoglobin level measurement in the emergency department. Amer J Emerg Med.https://doi.org/10.1016/j.ajem.2022.11.012.
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SpHb®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo SpHb, contribute to positive clinical outcomes and patient safety; risks that the researchers’ conclusions and findings may be inaccurate; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Launch of the FIB-SEM System “JIB-PS500i” with High Precision and High Resolution1.2.2023 02:00:00 CET | Press release
JEOL Ltd. (TOKYO:6951) (President & CEO Izumi Oi) announces its launch of the FIB-SEM system “JIB-PS500i” on February 1, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230123005841/en/ FIB-SEM System "PS500i" (Photo: Business Wire) With the finer structure of advanced materials and advancing complexity of processes, evaluation techniques such as morphological observation and elemental analysis require higher resolution and precision. In the preparation of samples for transmission electron microscopes (TEM) in the semiconductor industry as well as in the battery and materials fields, "higher precision" and "thinner sample" are required. This product is a combined system of the FIB (Focused Ion Beam) system that can process with high accuracy and the SEM (scanning electron microscope) of high resolution to satisfy these needs. Main Features The FIB column enables processing with a large-current Ga ion beam up to 100nA. T
PMI Recognized in 2023 Bloomberg Gender-Equality Index for Third Consecutive Year31.1.2023 22:00:00 CET | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that it has been included in the 2023 Bloomberg Gender-Equality Index (GEI) for the third year running. With an overall score of 80.6%, surpassing the index average score of 73%, PMI joins an A-list of global companies committed to transparency in gender reporting and advancing equality in the workplace. “Achieving gender balance at all levels of the company is one of our top priorities, and I am delighted that our efforts are recognized again in this year’s index,” commented Silke Muenster, Chief Diversity Officer at PMI. “While we are making significant progress, we know we need to keep our foot on the acceleration pedal. An inclusive workplace that leverages the full talents of both women and men is crucial to our smoke-free vision, making our organization more innovative, resourceful, and engaged.” In 2022, PMI achieved its target of ensuring at least 40% female representation in managerial roles and announced a new
CORRECTING and REPLACING Andersen Global Caps Another Year of Strong Growth with the Addition of 11 New Member Firms Worldwide31.1.2023 21:19:00 CET | Press release
Tenth bullet point in release should read: MGC Legal (Turkey) (instead of MCG Legal (Turkey)). Additionally, remove Bangladesh from the list of countries in the Africa section. The updated release reads: ANDERSEN GLOBAL CAPS ANOTHER YEAR OF STRONG GROWTH WITH THE ADDITION OF 11 NEW MEMBER FIRMS WORLDWIDE Growing Global Footprint Provides Multinational Clients with Independent, Best-In-Class, Multidisciplinary Services Andersen Global, the worldwide leader in tax and legal services, welcomes 11 member firms to its platform, increasing its ability to provide independent, multidisciplinary, borderless service to its global clients. Through its member and collaborating firms, Andersen Global has over 13,000 professionals and a presence in over 390 locations in more than 170 countries on six continents, giving it one of the largest global footprints among multinational, multidisciplinary professional services firms. New member firms of the organization include: A&A Tax (Australia) Law Firm
KartRider: Drift Races Into Its Inaugural Season With Console Cross-play Date Reveal31.1.2023 19:01:00 CET | Press release
KartRider: Drift, Nexon’s completely free-to-play kart racing title, announced today its Season One date when consoles will join the online racing mix. Current Preseason PC and mobile racers on Steam, Nexon Launcher, Android, and iOS, will soon be able to compete head-to-head against Xbox and PlayStation players from all over the globe in thrilling, drift-fueled racing. Full cross-platform, cross-play will be available when Season One “New World” arrives on March 8. Season One also brings with it exciting new content – brand new tracks and race modes, a season-long theme, daily player rewards and events, plus many other improvements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005459/en/ Nexon's "KartRider: Drift" Announces March 8 Season One Arrival Date With New Gameplay Trailer. (Graphic: Business Wire) KartRider: Drift isn’t as simple as it may seem! The easy-to-learn, hard-to-master game offers distinct game mo
PPG achieves ISO 14001 certification of environmental management system31.1.2023 16:00:00 CET | Press release
PPG (NYSE: PPG) today announced that it has achieved International Organization for Standardization (ISO) 14001 certification for an environmental management system (EMS) at its Shannon, Ireland, operations. The company manufactures highly efficient, high-performing organic light-emitting diode (OLED) materials at the Universal Display Corporation (UDC) (Nasdaq: OLED) site. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005097/en/ PPG produces phosphorescent organic light-emitting diode (OLED) materials and technologies for Universal Display Corporation (UDC) that are up to four times more energy-efficient than conventional fluorescent OLED materials. UDC’s proprietary UniversalPHOLED® technology enhances the performance of consumer displays and lighting products by providing power savings that enable longer battery life in portable electronics and less energy consumption in larger display and lighting products. (Photo